← NuCana plc (NCNA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
NuCana plc (NCNA)
Pharmaceutical Preparations · market cap $5M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
NuCana plc (NCNA) is a micro-cap pharmaceutical preparations company trading at approximately $1.32 with a reported market cap of ~$39,747M — a figure that appears inconsistent with its share price and warrants verification. The company operates with only 20 employees, has no lead asset identified in available data, and carries an elevated dilution risk flag of 24% with no analyst coverage.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
No pipeline data.
Price & technical context
3-month
-14.0%
6-month
-24.0%
12-month
-74.8%
52-wk range
$1.17–$7.02
vs 50-day MA
-15.6%
vs 200-day MA
-41.7%
Realized vol
86.8%
Max drawdown
-99.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NCNA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.